Industry
Biotechnology
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Charles Gross
July 17, 2023 | 9:14 pm
Portfolio Pulse from Benzinga Insights
July 17, 2023 | 4:17 pm
Portfolio Pulse from Benzinga Insights
July 06, 2023 | 5:37 pm
Portfolio Pulse from Lisa Levin
July 06, 2023 | 1:52 pm
Portfolio Pulse from Benzinga Insights
July 06, 2023 | 1:12 pm
Portfolio Pulse from Lisa Levin
July 06, 2023 | 12:04 pm
Portfolio Pulse from Benzinga Newsdesk
July 06, 2023 | 10:14 am
Portfolio Pulse from Benzinga Newsdesk
July 06, 2023 | 10:02 am
Portfolio Pulse from Benzinga Newsbot
July 06, 2023 | 12:48 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.